Search research articles
Contact Us
Filters
Showing results (131-140 of 155) with videos related to
Page
of 16
Sort By:
BJU International
|
October 27, 2021
Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial
Yasmin Abu-Ghanem, Johannes V van Thienen, Christian Blank, et al.
The Lancet. Oncology
|
January 8, 2020
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
Matthias Guckenberger, Yolande Lievens, Angelique B Bouma, et al.
The Lancet. Oncology
|
May 18, 2013
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data
Audrey Mauguen, Jean-Pierre Pignon, Sarah Burdett, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 2, 2008
Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'
Sandra Collette, Laurence Collette, Tom Budiharto, et al.
JAMA Oncology
|
December 14, 2018
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial
Axel Bex, Peter Mulders, Michael Jewett, et al.
The New England Journal of Medicine
|
July 23, 2015
Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer
Philip M Poortmans, Sandra Collette, Carine Kirkove, et al.
European Urology
|
June 23, 2019
Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME)
Roderick Emile De Bruijn, Peter Mulders, Michael A Jewett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2016
Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991
Michel Bolla, Philippe Maingon, Christian Carrie, et al.
JAMA Oncology
|
September 9, 2016
Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial
Conny Vrieling, Erik van Werkhoven, Philippe Maingon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 26, 2021
Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease
Michel Bolla, Anouk Neven, Philippe Maingon, et al.
Page
of 16
Search research articles
Search
Showing results (131-140 of 155) with videos related to
Sort By:
Page
of 16
BJU International
|
October 27, 2021
Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial
Yasmin Abu-Ghanem, Johannes V van Thienen, Christian Blank, et al.
The Lancet. Oncology
|
January 8, 2020
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
Matthias Guckenberger, Yolande Lievens, Angelique B Bouma, et al.
The Lancet. Oncology
|
May 18, 2013
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data
Audrey Mauguen, Jean-Pierre Pignon, Sarah Burdett, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 2, 2008
Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'
Sandra Collette, Laurence Collette, Tom Budiharto, et al.
JAMA Oncology
|
December 14, 2018
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial
Axel Bex, Peter Mulders, Michael Jewett, et al.
The New England Journal of Medicine
|
July 23, 2015
Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer
Philip M Poortmans, Sandra Collette, Carine Kirkove, et al.
European Urology
|
June 23, 2019
Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME)
Roderick Emile De Bruijn, Peter Mulders, Michael A Jewett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2016
Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991
Michel Bolla, Philippe Maingon, Christian Carrie, et al.
JAMA Oncology
|
September 9, 2016
Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial
Conny Vrieling, Erik van Werkhoven, Philippe Maingon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 26, 2021
Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease
Michel Bolla, Anouk Neven, Philippe Maingon, et al.
Page
of 16